Impaired Regulation of Glucose Transporter 4 ... - Semantic Scholar

2 downloads 0 Views 218KB Size Report
Valdez R, Athens MA, Thompson GH, Bradshaw BS, Stern MP. 1994 Birth ... De Fronzo RA, Tobin JD, Andres R. 1979 Glucose clamp technique: a method.
0021-972X/01/$03.00/0 The Journal of Clinical Endocrinology & Metabolism Copyright © 2001 by The Endocrine Society

Vol. 86, No. 7 Printed in U.S.A.

Impaired Regulation of Glucose Transporter 4 Gene Expression in Insulin Resistance Associated with in Utero Undernutrition* D. JAQUET†, H. VIDAL, R. HANKARD, P. CZERNICHOW,

AND

C. LEVY-MARCHAL

INSERM, U-457 (D.J., P.C., C.L.-M.), and Clinical Investigation Unit (R.H.), Hoˆpital Robert Debre´, 75019 Paris, France; and INSERM, U-449, and Genalys, Faculte´ de Me´decine Laennec (H.V.), 69372 Lyon, France ABSTRACT The aim of this study was to investigate whether insulin resistance-associated in utero undernutrition was related to changes in insulin action on gene expression of molecules involved in the insulin signaling pathway and peripheral glucose metabolism in muscle and adipose tissue. Thirteen insulin-resistant subjects born with intrauterine growth retardation (IUGR) were matched for age, gender, and body mass index to 13 controls. Gene expression of insulin receptor, insulin receptor substrate-1, p85␣ phosphatidylinositol 3-kinase, glucose transporter-4 (GLUT4), hexokinase II, and glycogen synthase was studied in skeletal muscle at baseline and after a 3-h euglycemic insulin stimulation. Target messenger ribonucleic acid (mRNA) levels were quantified using the RT-competitive PCR method. Insulin-stimulated glucose uptake was significantly lower in IUGR-born subjects than in controls (36.9 ⫾ 12, 7 vs. 53.9 ⫾ 12.7 ␮mol/kg䡠min; P ⫽ 0.007), affecting both the glucose oxidation rate and the nonoxidative glucose

T

HE ASSOCIATION between in utero undernutrition and the later impairment of glucose tolerance or type 2 diabetes is now well established (1, 2). Several recent reports support the hypothesis that this association involves a prior step of insulin resistance as observed in common forms of type 2 diabetes (3–5). In a cohort of young adults (25 yr old) selected from birth data, we have shown that subjects born with intrauterine growth retardation (IUGR) demonstrated hyperinsulinemia and insulin resistance, with normal glucose tolerance (6, 7). However, the mechanisms by which in utero undernutrition leads to the development of insulin resistance in adulthood remain unknown. To explain the high prevalence of type 2 diabetes in Western populations, Neel has hypothesized that genes that would favor survival at a time of famine would become detrimental when food supply is abundant. These genes build the thrifty genotype (8). Moreover, it has been recently proposed that genetic predisposition to insulin resistance might represent a selective survival advantage in low birth weight infants (9). We speculated that such a genetic preReceived November 10, 2000. Revision received February 5, 2001. Rerevision received March 21, 2001. Accepted March 23, 2001. Address all correspondence and requests for reprints to: Dr. D. Jaquet, INSERM, U-457, Hoˆpital Robert Debre´, 75019 Paris, France. E-mail: [email protected]. * This work was supported in part by Pharmacia-Upjohn (St. Quentin-en-Yveunes, France) and a grant from La Fondation de France. † Supported by a fellowship from INSERM sponsored by Bayer Corp.-France.

disposal rate. At baseline, the expression of the six genes in muscle did not significantly differ between the two groups. The insulininduced changes over baseline were comparable in both groups for all mRNAs, except GLUT4. In contrast to what observed in the control group (mean increment, 49 ⫾ 23%; P ⫽ 0.0009), GLUT4 expression was not stimulated by insulin in the IUGR group (8 ⫾ 8%; P ⫽ 0.42). Moreover, the magnitude of the defect in GLUT4 mRNA regulation by insulin was correlated to the degree of insulin resistance (r ⫽ 0.73; P ⫽ 0.01). A similar lack of significant GLUT4 mRNA stimulation by insulin was observed in the adipose tissue of IUGR-born subjects. In conclusion, insulin resistance in IUGR-born subjects is associated with an impaired regulation of GLUT4 expression by insulin in muscle and adipose tissue. Our data provide additional information about the mechanism of insulin resistance associated with in utero undernutrition and strengthen the role of glucose transport in the control of insulin sensitivity. (J Clin Endocrinol Metab 86: 3266 –3271, 2001)

disposition could alter the control of gene expression of the molecules involved in insulin action. The aim of the present study was therefore to investigate whether early adult-onset insulin resistance associated with in utero undernutrition would be related to an impaired expression and/or an altered regulation of genes involved in the insulin signaling pathway and the peripheral glucose utilization. For this purpose, gene expression of insulin receptor, insulin receptor substrate-1 (IRS-1), p85␣ regulatory subunit of the phosphatidylinositol 3-kinase (p85␣PI-3K), glucose transporter-4 (GLUT4), hexokinase II, and glycogen synthase were measured in the basal state and after insulin infusion in muscle and adipose tissue biopsies from controls and insulin-resistant IUGR-born subjects. Subjects and Methods Subjects The study population consisted of 13 insulin-resistant subjects born with IUGR and 13 controls recruited from the regional cohort of the city of Haguenau in which subjects had been selected from birth data (6). All subjects were of Caucasian origin. IUGR was defined as a birth weight below the third percentile of the local distribution for gender and gestational age (10). Control subjects, selected for birth weight between the 25th and the 75th percentiles of the same distribution, were matched for age, gender, and body mass index at the time of the study to the IUGR-born subjects. The clinical characteristics of the 2 groups at birth and at the time of the study are summarized in Table 1. As expected, mean birth weight and ponderal index were significantly reduced in the IUGR group. According to the selection criteria, there were no significant differences between the 2 groups in terms of age, gender distribution,

3266

GLUT4 EXPRESSION IN IUGR SUBJECTS TABLE 1. Clinical characteristics at birth and at the time of the study in the IUGR-born and control subjects

Birth wt (g) Ponderal index (kg/m3) Gestational age (weeks) Age (yr) Gender (M/F) Wt (kg) BMI (kg/m2) Total body fat (%) Waist/hip ratio

IUGR (n ⫽ 13)

Control (n ⫽ 13)

P

2369 ⫾ 297 22.8 ⫾ 3.0 39.3 ⫾ 1.6 25.3 ⫾ 1.8 6/7 71.5 ⫾ 22.5 24.6 ⫾ 6.4 26.1 ⫾ 7.2 0.79 ⫾ 0.11

3431 ⫾ 244 26.7 ⫾ 1.3 39.7 ⫾ 1.3 25.3 ⫾ 2.1 6/7 69.2 ⫾ 12.3 24.0 ⫾ 3.0 23.2 ⫾ 7.8 0.82 ⫾ 0.08

⬍0.0001 0.0003 0.35 ⬎0.99 ⬎0.99 0.88 0.55 0.40 0.33

Results are expressed as the mean ⫾ SD. P values are given for the statistical comparisons between the two groups using the MannWhitney U test for continuous variable and the ␹2 test for class variables.

3267

Analytical methods Plasma glucose concentrations during the clamp were measured by the glucose oxidase method with an on-site analyzer (Beckman Coulter, Inc., Fullerton, CA). Plasma insulin concentrations were measured using a double antibody RIA (ERIA Diagnostics Pasteur, Paris, France). Cross-reactivity with proinsulin and derived metabolites was less than 1%. Assay sensitivity was 1.2 pmol/L, and intra- and interassays coefficients of variations were 3.8% and 8% at 48 pmol/L, respectively, and 2.4% and 4.8% at 300 pmol/L, respectively. Plasma isotopic enrichment of [6,6-2H2]glucose was determined by gas chromatography-mass spectrometry (5971 MSD, Hewlett-Packard Co., Palo Alto, CA). Mean values of the intraindividual coefficients of variation of the plasma isotopic enrichment of [6,6-2H2] glucose at steady state were 4.9 ⫾ 2.1% and 7.2 ⫾ 2.2% at baseline and during the hyperinsulinemic clamp, respectively.

Muscle and adipose tissue biopsies ‘and anthropometric parameters at the time of the study. Parental history of type 2 diabetes (P ⫽ 0.59), dyslipidemia (P ⫽ 0.64), and hypertension (P ⬎ 0.99) did not significantly differ between the 2 groups. All subjects had normal glucose tolerance during an oral glucose tolerance test, according to American Diabetes Association criteria (11). All subjects gave their written informed consent, and the study protocol was reviewed and approved by the ethics committee of the Paris/St. Louis School of Medicine.

Muscle and adipose tissue biopsies were performed under local anesthesia (2% lidocaine) at baseline and after the 3-h insulin infusion, as previously described (13–15). Muscle biopsies were obtained percutaneously from the vastus lateralis using a Weil Blakesley plier (wet weight, 58 ⫾ 4 mg, with no significant difference in sample sizes between the IUGR and control subjects). Abdominal sc adipose tissue was aspirated from the periombilical area through a 15-gauge needle (wet weight, 259 ⫾ 16 mg, with no significant difference in sample sizes between IUGR and control subjects). Tissue samples were immediately frozen in liquid nitrogen and stored at ⫺80 C for further analysis.

Tests and methods Assessment of total body fat mass. The percentage of total body fat mass was calculated after bioelectrical impedance analysis (RJL Systems, Clinton Township, NJ). Euglycemic hyperinsulinemic clamp. Subjects were admitted to the Clinical Investigation Unit at Robert Debre´ Hospital (Paris, France). A 3-h euglycemic hyperinsulinemic clamp was performed after a 10-h fast as previously described (12). Insulin was infused throughout the test at 80 mU/m2䡠min. To maintain plasma glucose concentrations at 100 ⫾ 10 mg/dL during the clamp, adjustment of glucose infusion was made from the results of plasma glucose measured every 5 min during the first hour and the two measurement periods. In between, adjustment was performed every 10 min. Peripheral glucose uptake was calculated as the average glucose infusion rate during two consecutive 20-min periods (140 –180 min) and was corrected for a target value of plasma glucose at 5.5 mmol/L. At steady state, mean plasma glucose concentrations were similar in the IUGR and control groups (5.44 ⫾ 0.11 vs. 5.39 ⫾ 0.11 mmol/L, respectively). Intraindividual coefficients of variations of plasma glucose during the first and the second periods were 1.9 ⫾ 0.5% and 1.9 ⫾ 0.6%, respectively. Serum insulin concentrations measured at steady state did not differ between IUGR-born subjects and controls (1224 ⫾ 420 vs. 1244 ⫾ 396 pmol/L; P ⫽ 0.85). The glucose turnover rate was determined by the tracer dilution method. A priming dose (5 mg/kg) of [6,6-2H2]glucose (Eurisotop, St. Aubain, France) was given 90 min before the clamp was started, followed by a continuous infusion (5 mg/kg䡠h) throughout the basal and clamp periods. [6,6-2H2]Glucose isotopic enrichment was determined from blood samples drawn every 10 min during the last 30 min of the basal period and during the last 40 min of the euglycemic clamp. Endogenous glucose production was calculated at baseline and at the end of the euglycemic clamp using steady state equations (13). To calculate glucose oxidation rate, respiratory exchange measurements were taken during the final 30 min of both the basal and clamp periods using indirect calorimetry (GEN, Europa-Scientific, Crewe, UK). Steady state was obtained when the intraindividual coefficient of variation of the respiratory exchange measurements was less than 10% during at least 20 min. The nonoxidative glucose disposal rate was calculated as the difference between the peripheral glucose uptake and the glucose oxidation rate.

Total RNA preparation Tissue samples were pulverized in liquid nitrogen. Total RNAs were isolated from muscle biopsies using the TRIzol reagent (Life Technologies, Inc., Cergy-Pontoise, France). The yield in total RNA was 25.7 ⫾ 2.5 ␮g/100 mg muscle tissue (wet weight). For adipose tissue, total RNAs were prepared using the RNeasy total RNA kit (QIAGEN, Courtaboeuf, France). The recovery was 1.4 ⫾ 0.1 ␮g/100 mg tissue (wet weight). The 260 –280 nm absorbance ratio was between 1.8 –2 for all preparations. Total messenger RNA (mRNA) solutions were stored at ⫺80 C until quantification of the target mRNAs.

Quantification of target mRNAs The absolute mRNA concentrations of the six selected genes were measured by RT-competitive PCR (RT-cPCR), a method that relies on the use of a competitor DNA molecule during the amplification process, after a specific RT reaction (13, 14). The conditions of the RT have been defined to warrant maximal efficiency of first strand complementary DNA synthesis (14), and the competitive PCR has been clearly demonstrated to be a real quantitative method to determine the steady state expression levels of specific mRNAs (14). Insulin receptor, IRS-1, and glycogen synthase mRNAs were quantified using a multispecific competitor DNA that was constructed and validated previously (13). For the assays of the mRNAs encoding GLUT4, p85␣PI-3K and hexokinase II, we used another competitor DNA molecule that was recently developed and validated (16). The sequences of the primers used for the RT-cPCR assays are indicated in the previous publications (13, 16). The conditions of the RT-cPCR reactions have been described in details previously (13, 14). For each mRNA, the specific first strand complementary DNA was synthesized from 0.1 ␮g of total RNA added in the RT reaction. During the PCR, we used sense primers that were 5⬘-end labeled with Cy-5 fluorescent dye (Eurogentec, Seraing, Belgium). The PCR products were then analyzed with an automated laser fluorescence DNA sequencer (ALFexpress, Pharmacia, Upsala, Sweden) in denaturating 4% polyacrylamide gels (15, 16). The amounts of PCR products (competitor and target) were calculated by integrating peak areas using Pharmacia Fragment Manager software from. To determine the initial concentration of the target mRNA, the logarithm of the peak surface ratio of competitor to target was plotted against the logarithm of the amount of competitor added into the PCR medium. The initial concentration of the target was determined at the competition equiva-

3268

JAQUET ET AL.

lence point as previously described (14). Coefficients of variation range from 5 to 17% according to the mRNA tested (14).

Statistical analyses All data were entered and analyzed on the StatView 5.0 statistical package. (SAS Institute, Inc., Cary, NC). Nonparametric tests were used for continuous variables because of the small sample size and the skewed distributions of the data. The Mann-Whitney U test was used for the comparison between the IUGR and control groups. The paired Wilcoxon test was used in each group for the comparisons of gene expression changes under insulin stimulation vs. baseline. The relationship between changes in gene expression after insulin stimulation and the peripheral glucose uptake values were analyzed using a linear regression model. P ⱕ 0.05 was considered significant.

Results Metabolic parameters

At baseline, mean values of fasting plasma glucose were comparable between the IUGR and control groups (4.90 ⫾ 0.44 vs. 4.79 ⫾ 0.39 mmol/L; P ⫽ 0.68). Endogenous glucose production did not significantly differ between the two groups (11.6 ⫾ 2.2 vs. 12.1 ⫾ 1.1 ␮mol/kg䡠min; P ⫽ 0.52). The glucose oxidation rate was slightly lower in the IUGR group, but the difference did not reach statistical significance (8.8 ⫾ 2.2 vs. 10.5 ⫾ 2.8 ␮mol/kg䡠min; P ⫽ 0.06). Serum fasting triglycerides (1.47 ⫾ 0.87 vs. 1.21 ⫾ 1.15 mmol/L; P ⫽ 0.34), total cholesterol (4.73 ⫾ 0.59 vs. 4.45 ⫾ 0.74 mmol/L; P ⫽ 0.45) and high density lipoprotein cholesterol (1.62 ⫾ 0.63 vs. 1.41 ⫾ 0.42 mmol/L; P ⫽ 0.44) did not significantly differ between IUGR-born and control subjects. As shown in Fig. 1, at steady state under insulin stimulation, peripheral glucose uptake, the glucose oxidation rate,

FIG. 1. Peripheral glucose uptake, glucose oxidation rate, and nonoxidative glucose disposal rate in the IUGR (f) and control (䡺) groups. Values were obtained after a 3-h insulin infusion (80 mU/ m2䡠min) at steady state of a euglycemic hyperinsulinemic clamp. Results are given as the mean ⫾ SD. Satistical significance is given for the comparison between the two study groups using a nonparametric Mann-Whitney U test. PGU, Peripheral glucose uptake; NOXGDR, nonoxidative glucose disposal rate; GOXR, glucose oxidation rate.

JCE & M • 2001 Vol. 86 • No. 7

and the nonoxidative glucose disposal rate were reduced in the IUGR-born subjects. The relative specific contributions of glucose oxidation rate (45 ⫾ 13% vs. 40 ⫾ 6%), on the one hand, and the nonoxidative glucose disposal rate (55 ⫾ 13% vs. 60 ⫾ 6%), on the other hand, to the peripheral glucose uptake under insulin stimulation did not significantly differ between the IUGR and control groups (P ⫽ 0.17). This suggests that both components of peripheral glucose uptake were equally affected in the IUGR group. Endogenous glucose production was similarly suppressed in the two groups under insulin stimulation (⫺7.2 ⫾ 7.7 vs. 7.7 ⫾ 6.1 ␮mol/ kg䡠min; P ⫽ 0.58). Expression of the target mRNAs in skeletal muscle and effect of insulin infusion

The mRNA levels (expressed as attomoles per ␮g total RNA) for genes encoding key proteins of the insulin signaling pathway, namely insulin receptor, IRS-1, and p85␣PI-3K, or key proteins involved in peripheral glucose utilization (GLUT4, hexokinase II, and glycogen synthase) were determined in skeletal muscle by RT-cPCR. The mean concentrations of these transcripts in the basal state in the two groups are given in Table 2A. There were no statistically significant differences between the IUGR and control groups in basal mRNA expression of the six target genes. After a 3-h insulin infusion, a significant increase over baseline in p85␣PI-3K mRNA expression in the IUGR and control groups was observed. Conversely, a significant reduction of IRS-1 mRNA expression was noted in both groups (values expressed as the percent change over baseline are given in Table 2B). Insulin infusion did not significantly affect the mRNA level of insulin receptor in either IUGRborn subjects or controls (Table 2B). When compared between the two study groups, the mean percent changes over baseline of expression of these three genes did not show any statistically significant differences. With respect to the molecules involved in peripheral glucose utilization, insulin infusion had no statistically significant effect on glycogen synthase mRNA expression in both IUGR and control groups (Table 2). Conversely, hyperinsulinemia significantly increased hexokinase II mRNA expression compared with baseline in both IUGR-born and control subjects (Table 2). When the two study groups were compared, the magnitude of the insulin-induced changes over baseline in the mRNA expression of these two genes did not significantly differ (Table 2B). GLUT4 mRNA expression was significantly increased during insulin infusion in the control group and the relative increment over baseline (⫹49 ⫾ 23%) was statistically significant (Fig. 2). By contrast, as illustrated in Fig. 2, insulin infusion had no significant effect on GLUT4 mRNA expression in the IUGR group (relative increment over baseline, ⫹8 ⫾ 8%; P ⫽ 0.85). A positive and significant correlation was observed between the relative changes in GLUT4 mRNA expression during insulin infusion and the values of peripheral glucose uptake in the IUGR group (r ⫽ 0.73; P ⫽ 0.01; Fig. 3). No significant correlation was found in the control group (r ⫽ 0.006; P ⫽ 0.98). No other significant correlation was observed between the

GLUT4 EXPRESSION IN IUGR SUBJECTS

3269

TABLE 2. Basal values of the transcripts of target genes in muscle (A) and their changes after insulin stimulation (B) in the IUGR and control groups IUGR (n ⫽ 13)

A. Baseline Insulin signaling pathway Insulin receptor (amol/␮g total RNA) 10.9 ⫾ 1.8 IRS-1 (amol/␮g total RNA) 20.8 ⫾ 3.9 p85␣ PI-3K (amol/␮g total RNA) 13.2 ⫾ 2.5 Peripheral glucose utilization GLUT 4 (amol/␮g total RNA) 28.9 ⫾ 1.5 Hexokinase II (amol/␮g total RNA) 2.4 ⫾ 0.3 Glycogen synthase (amol/␮g total RNA) 233 ⫾ 21 B. Relative changes over baseline after insulin stimulation Insulin signaling pathway Insulin receptor (%) ⫹33 ⫾ 14a IRS-1 (%) ⫺33 ⫾ 6b p85␣ PI-3K (%) ⫹97 ⫾ 37c Peripheral glucose utilization GLUT 4 (%) ⫹8 ⫾ 8a Hexokinase II (%) ⫹98 ⫾ 26c Glycogen synthase (%) ⫹17 ⫾ 10a

Control (n ⫽ 13)

P

10.3 ⫾ 1.1 13.7 ⫾ 2.0 9.4 ⫾ 1.3

0.78 0.12 0.43

27.0 ⫾ 1.6 2.6 ⫾ 0.4 231 ⫾ 22

0.48 0.79 0.94

⫹15 ⫾ 63a ⫺33 ⫾ 8b ⫹78 ⫾ 20c

0.26 0.85 0.84

⫹49 ⫾ 23b ⫹73 ⫾ 41b ⫹11 ⫾ 17a

0.09 0.16 0.85

Results are expressed as the mean ⫾ SEM. Values for expression of the target genes after insulin stimulation are expressed as the percent change over basal values. The statistical significance of these changes of the target genes expression in comparison to baseline was tested using the paired Wilcoxon test in each group. Results are indicated as exponent symbols in each group and for each target gene. P values for the statistical comparisons of the differences in the relative changes between the two study groups using the Mann-Whitney U test are given in the right column. a P ⫽ NS. b P ⬍ 0.01. c P ⬍ 0.05.

changes in mRNA expression of the other genes and peripheral glucose uptake in either study group. Effect of insulin infusion on GLUT4 mRNA expression in adipose tissue

The lack of significant stimulation of GLUT4 mRNA expression by insulin in muscle led us to investigate whether the same impairment would also prevail in the adipose tissue of IUGR-born subjects. In sc abdominal adipose tissue, GLUT4 mRNA expression at baseline did not significantly differ between IUGR and control subjects (45.8 ⫾ 8.6 vs. 57.3 ⫾ 8.6 attomoles/␮g total mRNA; P ⫽ 0.57). Figure 2 shows that, as in skeletal muscle, insulin infusion for 3 h failed to have a significant effect in IUGR subjects; the relative increment in GLUT4 expression over baseline was ⫹32 ⫾ 19%, and the comparison was not statistically significant vs. baseline (P ⫽ 0.25). Conversely, GLUT4 mRNA levels were significantly increased in adipose tissue of the control subjects (⫹94 ⫾ 27%; P ⫽ 0.01). When the two study groups were compared, the insulin-induced relative changes in GLUT4 mRNA expression in the adipose tissue reached the same level of significance as those in muscle (8 ⫾ 8% vs. 49 ⫾ 23%; P ⫽ 0.09). Discussion

The main finding of our study is that insulin resistance is associated with an impaired regulation of GLUT4 gene expression by insulin in IUGR-born subjects that is observed in both skeletal muscle and adipose tissue. All subjects included in the present study had been precisely selected on birth data, and both groups were carefully matched for age, gender, and body mass index. Additionally, the two groups were comparable in terms of parental history of type 2 diabetes, dys-

lipidemia, or hypertension. Therefore, the insulin resistance observed in the IUGR group is probably related to in utero undernutrition itself and not to other confounding factors. Interestingly, in the IUGR group, the magnitude of the defect in GLUT4 mRNA regulation by insulin in muscle was correlated to the degree of insulin resistance assessed by the insulin-stimulated glucose uptake. No such a correlation was found when changes in hexokinase II or glycogen synthase mRNA expression under insulin stimulation were analyzed. In addition, mRNA expression of these two genes did not significantly differ between the IUGR and control groups either at baseline or under insulin stimulation. These observations are consistent with the metabolic abnormalities observed in the IUGR-born subjects. Indeed, our data show that under insulin stimulation, both the glucose oxidation rate and the nonoxidative glucose disposal rate are affected in IUGR-born subjects, suggesting that these two components account for the decreased insulin sensitivity. Taken together, our data suggest that an impaired regulation of GLUT4 gene expression might contribute to the insulin resistance associated with in utero undernutrition, strengthening the role of glucose transport in the control of insulin sensitivity. Nevertheless, further studies investigating the consequences of this abnormality at the protein level are necessary, and the mechanism by which GLUT4 might be involved in this case of insulin resistance should be examined. The question of whether the impaired regulation by insulin of GLUT4 gene expression observed in insulin-resistant IUGR-born subjects is a consequence of the insulin resistance itself or whether it is rather related to in utero undernutrition remains to be elucidated. GLUT4 expression at baseline was comparable in muscle of IUGR-born and control subjects.

3270

JAQUET ET AL.

JCE & M • 2001 Vol. 86 • No. 7

FIG. 3. Correlation between the relative variation of GLUT4 mRNA expression (percentage) induced by insulin in muscle and e peripheral glucose uptake in the IUGR group. The relative change in GLUT4 expression is calculated as the percent change in the GLUT4 mRNA level induced by insulin stimulation compared with the basal value. The peripheral glucose uptake was calculated at steady state of a euglycemic hyperinsulinemic clamp after 3-h insulin infusion at 80 mU/m2䡠min.

FIG. 2. GLUT4 mRNA expression in muscle (A) and adipose tissue (B) in the basal state and after insulin infusion in the IUGR and control groups. 䡺, Results obtained in the basal state; f, results obtained in the insulin-stimulated state. Results are given as means (SEM). **, P ⬍ 0.01. Statistical significance is given for the paired comparison between basal and insulin-stimulated states in each group, using a nonparametric paired Wilcoxon test.

This observation is in keeping with reports of normal GLUT4 mRNA levels in muscle from diabetic patients (16 –22). The acute regulation by insulin of GLUT4 gene expression in normal subjects and patients with insulin resistance has not been fully investigated in humans. Using a slot blot analysis, Andersen et al. previously reported that GLUT4 gene expression in muscle was acutely stimulated by short-term insulin stimulation in healthy subjects (21). By contrast, GLUT4 mRNA expression failed to increase under insulin infusion in type 2 diabetic patients and insulin-resistant first degree relatives (21, 23). Together, these data favor the idea that an impaired acute insulin stimulation of GLUT4 gene expression would reflect insulin resistance itself. Further in-

vestigations of GLUT4 gene expression and its regulation under other pathological conditions associated with insulin resistance will help clarify the proper role of in utero undernutrition on the impaired regulation by insulin of GLUT4 gene expression observed in IUGR-born adults. Unlike the blunted insulin stimulation of p85␣PI-3K gene expression reported in type 2 diabetic patients (15), we failed to observe any impairment in the expression and regulation by insulin of the major genes involved in the insulin signaling pathway (insulin receptor, IRS-1, and p85␣PI-3K) in the IUGR-born subjects. The insulin resistance observed in these subjects was not associated with an impaired expression of hexokinase II (16, 24) or glycogen synthase (16, 25), as previously shown in skeletal muscle of type 2 diabetic subjects. Together, these data suggest that the molecular mechanisms responsible for insulin resistance associated with type 2 diabetes mellitus or with in utero undernutrition may be different. Alternatively, the different pattern of expression of the key genes involved in insulin sensitivity could represent different degrees of progression of the disease. The comparison between IUGR-born adults with insulin resistance or overt diabetes would be extremely useful to distinguish between the two options. IUGR is known to severely alter the fetal development of adipose tissue (26), and we have previously reported that IUGR-born subjects selected within the same cohort showed traits of insulin resistance in the adipose tissue (7). In the present study insulin-resistant IUGR-born subjects demonstrated an impaired regulation by insulin of GLUT4 gene expression in the sc adipose tissue as opposed to the positive effect of insulin in the control subjects and previously reported in healthy young adults during a hyperinsulinemic clamp (27). Our results constitute the first observation of a defective regulation of GLUT4 gene expression in adipose tissue of insulin-resistant subjects, strengthening the hypothesis that adipose tissue could be

GLUT4 EXPRESSION IN IUGR SUBJECTS

a key component of the metabolic complications associated with in utero undernutrition. In conclusion, we have demonstrated that both the glucose oxidation rate and the nonoxidative disposal rate were affected by the insulin resistance associated with in utero undernutrition. These metabolic abnormalities are consistent with the impaired regulation by insulin of GLUT4 mRNA expression observed in both muscle and adipose tissue of insulin-resistant IUGR-born subjects. Although the consequences of such an impaired regulation of GLUT4 gene expression remain to be studied at the protein level, our results demonstrate that molecular abnormalities are already present in the insulin resistance observed in young, normoglycemic, IUGR-born adults. Moreover, our data provide an additional example of the contribution of glucose transport abnormalities to the pathophysiology of insulin resistance. Acknowledgments We acknowledge N. Vega for her excellent technical assistance. The authors thank Dr. D. Chevenne for his supervision of laboratory analyses. We also acknowledge the contributions of C.Traband, Dr. C. Collin, Dr. Boehrer, the laboratory staff at the Hospital of the City of Haguenau, and the nursing staff of the Clinical Investigation Unit of the Hospital R. Debre´ in supervising subjects.

References 1. Hales CN, Barker DJP, Clark PMS, et al. 1991 Fetal and infant growth and impaired glucose tolerance at age 64. Br Med J. 303:1019 –1022. 2. Lithell HO, McKeigue PM, Berglund L, Mohsen R, Lithell UB, Leon DA. 1996 Relation of size at birth to non-insulin dependent diabetes and insulin concentrations in men aged 50 – 60 years. Br Med J. 312:406 – 410. 3. Barker DJP, Hales CN, Fall C, Osmond C, Phipps K, Clark PMS. 1993 Type 2 (non-insulin-dependent) diabetes mellitus hypertension and hyperlipidaemia (syndrome X): relation to reduced fetal growth. Diabetologia. 36:62– 67. 4. Valdez R, Athens MA, Thompson GH, Bradshaw BS, Stern MP. 1994 Birth weight and adult health outcomes in a biethnic population in the USA. Diabetologia. 37:624 – 631. 5. Mc Keigue PM, Lithell HO, Leon DA. 1998 Glucose tolerance and resistance to insulin-stimulated glucose uptake in men aged 70 years in relation to size at birth. Diabetologia. 41:1133–1138. 6. Le´ger J, Le´vy-Marchal C, Bloch J, et al. 1997 Reduced final height and indications for insulin resistance in 20 year olds born small for gestational age: regional cohort study. Br Med J. 315:341–347. 7. Jaquet D, Gaboriau A, Czernichow P, Le´vy-Marchal C. 2000 Insulin-resistance early in adulthood in subjects born with intra-uterine growth retardation. J Clin Endocrinol Metab. 85:1401–1406. 8. Neel JV. 1962 Diabetes mellitus: a “thrifty” genotype rendered detrimental by “progress.” Am J Hum Genet. 14:353–362.

3271

9. McCance DR, Pettitt DJ, Hanson RL, Jacobsson LTH, Knwoler WC, Bennett PH. 1994 Birth weight and non insulin dependent diabetes: thrifty genotype, thrifty phenotype, or surviving small baby genotype? Br Med J. 308:942–945. 10. Papiernik E, Bouyer J, Dreyfus J, et al. 1985 Prevention of preterm births: a perinatal study in Haguenau, France. Pediatr. 76:154 –158. 11. Expert Committee on the Diagnosis and Classification of Diabetes Mellitus. 1997 Report of the expert committee on the diagnosis and classification of diabetes mellitus. Diabetes Care. 20:1183–1197. 12. De Fronzo RA, Tobin JD, Andres R. 1979 Glucose clamp technique: a method for quantifying insulin secretion and resistance. Am J Physiol. 237:E214 –E223. 13. Laville M, Auboeuf D, Khalfallah Y, Vega N, Riou JP, Vidal H. 1996 Acute regulation by insulin of phosphatidylinositol 3-kinase, Rad, GLUT 4 and lipoprotein lipase mRNA levels in human muscle. J Clin Invest. 98:43– 49. 14. Auboeuf D, Vidal H. 1997 The use of the reverse transcription-competitive polymerase chain reaction to investigate the in vivo regulation of gene expression in small tissue samples. Anal Biochem. 245:141–148. 15. Andreelli F, Laville M, Ducluzeau PH, et al. 1999 Defective regulation of phosphatidylinositol 3-kinase gene expression in skeletal muscle and adipose tissue of non-insulin dependent diabetes mellitus patients. Diabetologia. 42:358 –364. 16. Andreelli F, Laville M, Vega N, Riou JP, Vidal H. 2000 Regulation of gene expression during severe caloric restriction: lack of induction of p85 ␣ phosphatidylinositol 3-kinase mRNA in skeletal muscle of patients with type II (non-insulin-dependant) diabetes mellitus. Diabetologia. 43:356 –363. 17. Shepherd PR, Kahn BB. 1999 Glucose transporters and insulin action. N Engl J Med. 341:248 –257. 18. Shulman GI. 2000 Cellular mechanisms of insulin-resistance. J Clin Invest. 106:171–176. 19. Gould GW, Holman GD. 1993 The glucose transporter family: structure, function and tissue specific expression. Biochem J. 295:329 –341. 20. Zierath JR, He L, Guma A, Wahlstrom EO, Klip A, Walberg-Henriksson H. 1996 Insulin action on glucose transport and plasma membrane. GLUT 4 content in skeletal muscles from patients with NIDDM. Diabetologia. 39:1180 –1189. 21. Andersen PH, Lund S, Vestergaard H, Junker S, Kahn BB, Pedersen O. 1993 Expression of the major insulin regulatable glucose transporter (GLUT 4) in skeletal muscle of non insulin dependent diabetic patients and healthy subjects before and after insulin infusion. J Clin Endocrinol Metab. 77:27–32. 22. Garvey TW, Maianu L, Hancock JA, Golichowski AM, Baron A. 1992 Gene expression of GLUT 4 in skeletal muscle from insulin-resistant patients with obesity, IGT, GDM and NIDDM. Diabetes. 41:465– 475. 23. Schalin-Ja¨ntti C, Yki-Ja¨rvinen H, Koranyi L, et al. 1994 Effect of insulin on GLUT 4 mRNA and protein concentrations in skeletal muscle of patients with NIDDM and their first-degree relatives. Diabetologia. 37:401– 407. 24. Vestergaard H, Bjobæk C, Hansen T, Larsen FS, Granner DK, Pedersen O. 1995 Impaired activity and gene expression of hexokinase II in muscles form non-insulin-dependent diabetes mellitus patients. J Clin Invest. 96:2639 –2645. 25. Vestergaard H, Lund S, Larsen FS, Bjerrum OJ, Pedersen O. 1993 Glycogen synthase and phosphofructokinase protein and mRNA levels in skeletal muscles from insulin-resistant patients with non-insulin dependent diabetes mellitus. J Clin Invest. 91:2342–2350. 26. Widdowson EM, Southgate DAT, Hey EN. 1979 In: Visser HKA, ed. Nutrition and metabolism of the fetus and infant. The Hague: Martinus Nijhoff; 169 –177. 27. Vidal H, Auboeuf D, De Vos P. 1996 The expression of ob gene is not acutely regulated by insulin and fasting in human abdominal subcutaneous adipose tissue. J Clin Invest. 98:251–255.